Teva inks $200M global licensing deal with migraine rival Alder
Teva has struck a deal with rival migraine drug maker Alder BioPharmaceuticals, giving Alder a global license for eptinezumab for up to $200 million in milestones plus royalties.
The global non-exclusive license, signed by Teva’s subsidiary Teva Pharmaceuticals International GmbH, includes rights to develop, manufacture, and commercialize the drug in the US and worldwide, excluding Japan and Korea.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.